TAF5

Across TCGA pan-cancer cohorts, TAF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAF5 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TAF5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TAF5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where TAF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.985	0.596	<.001	33	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	6	view →
LSCC	DFS	Quartile	All	0.395	1.000	.040	4	view →
CCRCC	DFS	Median	IV	0.749	0.253	.044	2	view →
GBM	OS	Quartile	All	0.597	0.282	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAF5–LUAD (DFS)

Open the LUAD breakdown →